PL397563A1 - Pharmaceutical form comprising a therapeutically effective amount of an angiotensin II receptors AT1 - potassium losartan and a process for production thereof - Google Patents
Pharmaceutical form comprising a therapeutically effective amount of an angiotensin II receptors AT1 - potassium losartan and a process for production thereofInfo
- Publication number
- PL397563A1 PL397563A1 PL397563A PL39756311A PL397563A1 PL 397563 A1 PL397563 A1 PL 397563A1 PL 397563 A PL397563 A PL 397563A PL 39756311 A PL39756311 A PL 39756311A PL 397563 A1 PL397563 A1 PL 397563A1
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical form
- tablet
- angiotensin
- losartan
- potassium
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 102000008873 Angiotensin II receptor Human genes 0.000 title 1
- 108050000824 Angiotensin II receptor Proteins 0.000 title 1
- 239000003826 tablet Substances 0.000 abstract 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 2
- 239000007884 disintegrant Substances 0.000 abstract 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 abstract 2
- 229960001021 lactose monohydrate Drugs 0.000 abstract 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 abstract 2
- 102000005862 Angiotensin II Human genes 0.000 abstract 1
- 101800000733 Angiotensin-2 Proteins 0.000 abstract 1
- 239000002083 C09CA01 - Losartan Substances 0.000 abstract 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
- FDKIDFYIEWFERB-UHFFFAOYSA-N [2-butyl-5-chloro-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol;potassium Chemical compound [K].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 FDKIDFYIEWFERB-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 abstract 1
- 229950006323 angiotensin ii Drugs 0.000 abstract 1
- 239000007941 film coated tablet Substances 0.000 abstract 1
- 238000005243 fluidization Methods 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 229960000519 losartan potassium Drugs 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Postac farmaceutyczna zawierajaca terapeutycznie skuteczna ilosc antagonisty receptorów typu AT1 angiotensyny II, którym jest sól potasowa losartanu, charakteryzuje sie tym, ze stanowi ja tabletka powlekana zawierajaca substancje czynna - losartan potasu, naniesiony na nosnik, którym jest laktoza jednowodna, w ilosci od 10% do 27% wagowych w stosunku do calkowitej masy tabletki, oraz stearylofumaran sodu w ilosci od 2% do 3% wagowych w stosunku do calkowitej masy tabletki jako substancje poslizgowa i inne substancje pomocnicze wybrane sposród substancji wiazacych oraz substancji dezintegrujacych. Przedmiotem wynalazku jest takze sposób wytwarzania okreslonej powyzej postaci farmaceutycznej, który polega na tym, ze losartan potasu nanosi sie na ziarna jednowodnej laktozy w procesie granulacji fluidyzacyjnej, wytworzony granulat miesza sie z substancja wiazaca, substancja dezintegrujaca oraz substancja poslizgowa, która stanowi stearylofumaran sodu. Nastepnie wytworzona mieszanine tabletkuje sie, a rdzenie tabletek powleka.The pharmaceutical form containing a therapeutically effective amount of the angiotensin II type AT1 receptor antagonist, which is losartan potassium, is characterized by being a film-coated tablet containing the active substance - potassium losartan, applied to a carrier which is lactose monohydrate, in an amount of 10% to 27% by weight relative to the total weight of the tablet, and sodium stearyl fumarate in an amount of 2% to 3% by weight relative to the total weight of the tablet as a lubricant and other excipients selected from binders and disintegrants. The invention also relates to a process for the preparation of the above-described pharmaceutical form, which consists in the fact that potassium losartan is applied to grains of lactose monohydrate in a fluidization granulation process, the resulting granules are mixed with a binder, disintegrant and glidant, which is sodium stearyl fumarate. The resulting mixture is then tableted and the tablet cores coated.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL397563A PL218490B1 (en) | 2011-12-27 | 2011-12-27 | Pharmaceutical form comprising a therapeutically effective amount of an angiotensin II receptors AT1 - potassium losartan and a process for production thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL397563A PL218490B1 (en) | 2011-12-27 | 2011-12-27 | Pharmaceutical form comprising a therapeutically effective amount of an angiotensin II receptors AT1 - potassium losartan and a process for production thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL397563A1 true PL397563A1 (en) | 2013-07-08 |
| PL218490B1 PL218490B1 (en) | 2014-12-31 |
Family
ID=48748711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL397563A PL218490B1 (en) | 2011-12-27 | 2011-12-27 | Pharmaceutical form comprising a therapeutically effective amount of an angiotensin II receptors AT1 - potassium losartan and a process for production thereof |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL218490B1 (en) |
-
2011
- 2011-12-27 PL PL397563A patent/PL218490B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL218490B1 (en) | 2014-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2014000030A1 (en) | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators | |
| MX2013008431A (en) | Mineralocorticoid receptor antagonists. | |
| NZ589764A (en) | NMDA receptor antagonists for the treatment of neuropsychiatric disorders | |
| UA106057C2 (en) | Normal;heading 1;heading 2;heading 3;PREPARATION METHOD OF DIHYDROINDENE AMIDE COMPOUND, THEIR PHARMACEUTICAL COMPOSITION CONTAINING COMPOUNDS THEREOF AND USE AS PROTEIN KINASES INHIBITOR | |
| MX2014002394A (en) | Biphenylcarboxamides as rock kinase inhibitors. | |
| PH12014502341A1 (en) | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments | |
| UA115320C2 (en) | Kinase inhibitors | |
| EP4268814A3 (en) | Pharmaceutical composition for the treatment of dry eye | |
| MX2013012588A (en) | Kinase inhibitors. | |
| SG194756A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
| MX2013008296A (en) | Diarylacetylene hydrazide containing tyrosine kinase inhibitors. | |
| MY173408A (en) | Preparation of controlled release skeletal muscle relaxant dosage forms | |
| NZ703152A (en) | Dosing regimen for janus kinase (jak) inhibitors | |
| NZ628993A (en) | Pharmaceutical formulations comprising ccr3 antagonists | |
| PH12012502082A1 (en) | Combination of active loaded granules with additional actives | |
| PH12016500322A1 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
| AR100977A1 (en) | COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN, AND A PROCESS FOR PREPARATION | |
| PH12014501408A1 (en) | Immediate release multi unit pellet system | |
| MX337721B (en) | Heteroaryl compounds as 5-ht4 receptor ligands. | |
| MY161236A (en) | (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nachr | |
| MX345544B (en) | Triazole derivatives as ligands for gaba receptors. | |
| MX339858B (en) | Novel compounds as histamine h3 receptor ligands. | |
| WO2010136035A3 (en) | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof | |
| PH12016501625A1 (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | |
| PL397563A1 (en) | Pharmaceutical form comprising a therapeutically effective amount of an angiotensin II receptors AT1 - potassium losartan and a process for production thereof |